Manon Ripoll
Overview
Explore the profile of Manon Ripoll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
77
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hourdel L, Lebaz N, Peral F, Ripoll M, Briancon S, Bensaid F, et al.
Int J Pharm
. 2025 Feb;
672:125297.
PMID: 39900125
Nanoparticles carrying active drug substances have been used since the 70's and have undergone numerous improvements since then. Nowadays, the latest generation of nanoparticles, called lipid nanoparticles (LNPs), is used...
2.
Ripoll M, Cahuzac H, Dovgan I, Ursuegui S, Neuberg P, Erb S, et al.
Bioconjug Chem
. 2024 Sep;
PMID: 39321037
RNA interference is a widely used biological process by which double-stranded RNA induces sequence-specific gene silencing by targeting mRNA for degradation. However, the physicochemical properties of siRNAs make their delivery...
3.
Lemdani K, Marlin R, Mayet C, Perkov V, Pascal Q, Ripoll M, et al.
NPJ Vaccines
. 2024 Jun;
9(1):113.
PMID: 38902327
The characterization of vaccine distribution to relevant tissues after in vivo administration is critical to understanding their mechanisms of action. Vaccines based on mRNA lipid nanoparticles (LNPs) are now being...
4.
de Chateauneuf-Randon S, Bresson B, Ripoll M, Huille S, Barthel E, Monteux C
Nanoscale
. 2024 May;
16(22):10706-10714.
PMID: 38700424
For drug delivery systems, the mechanical properties of drug carriers are suspected to play a crucial role in the delivery process. However, there is a lack of reliable methods available...
5.
Lehot V, Neuberg P, Ripoll M, Daubeuf F, Erb S, Dovgan I, et al.
Pharmaceutics
. 2023 Jun;
15(6).
PMID: 37376091
Despite their clinical success, Antibody-Drug Conjugates (ADCs) are still limited to the delivery of a handful of cytotoxic small-molecule payloads. Adaptation of this successful format to the delivery of alternative...
6.
Bernard M, Bazin E, Petiot N, Lemdani K, Commandeur S, Verdelet C, et al.
Mol Ther Nucleic Acids
. 2023 Jun;
32:794-806.
PMID: 37346973
The use of modified nucleosides is an important approach to mitigate the intrinsic immunostimulatory activity of exogenous mRNA and to increase its translation for mRNA therapeutic applications. However, for vaccine...
7.
Ripoll M, Martin E, Enot M, Robbe O, Rapisarda C, Nicolai M, et al.
Sci Rep
. 2022 Jun;
12(1):9483.
PMID: 35676394
Lipid nanoparticles (LNPs) for RNA and DNA delivery have attracted considerable attention for their ability to treat a broad range of diseases and to vectorize mRNA for COVID vaccines. LNPs...
8.
Ripoll M, Bernard M, Vaure C, Bazin E, Commandeur S, Perkov V, et al.
Biomaterials
. 2022 May;
286:121570.
PMID: 35576809
The mRNA vaccine technology has promising applications to fight infectious diseases as demonstrated by the licensing of two mRNA-based vaccines, Comirnaty® (Pfizer/BioNtech) and Spikevax® (Moderna), in the context of the...
9.
Ripoll M, Pierdant M, Neuberg P, Bagnard D, Wagner A, Kichler A, et al.
RSC Adv
. 2022 May;
8(37):20758-20763.
PMID: 35542356
Recently, it has been shown that the efficiency of antitumoral drugs can be enhanced when combined with therapeutic siRNAs. In the present study, an original platform based on polydiacetylenic micelles...
10.
On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency
Dovgan I, Ehkirch A, Lehot V, Kuhn I, Koniev O, Kolodych S, et al.
Sci Rep
. 2020 May;
10(1):7691.
PMID: 32376903
Here we present the synthesis and evaluation of antibody-drug conjugates (ADCs), for which antibody and drug are non-covalently connected using complementary DNA linkers. These ADCs are composed of trastuzumab, an...